Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Receives Complete Response, Warning Letters For Lumizyme

Executive Summary

The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter

You may also be interested in...



Follow-On Biologics Debate May Divide PhRMA On Comparability Protocols

PhRMA President Tauzin acknowledges “there’s a little difference of opinion” among membership about what the criteria for interchangeability should be.

Follow-On Biologics Debate May Divide PhRMA On Comparability Protocols

PhRMA President Tauzin acknowledges “there’s a little difference of opinion” among membership about what the criteria for interchangeability should be.

Rationing Of Genzyme’s Myozyme In Europe Likely Through April Due To Supply Constraints

Until approval of the larger 4000 L bioreactor for the Pompe Disease product, EMEA recommends priority access for infants, children and adolescents.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel